Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + PRO1184 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
PRO1184 | PRO-1184|PRO 1184|Rinatabart Sesutecan|Rina-S|GEN1184 | FOLR1-targeted Therapy 24 | PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05579366 | Phase Ib/II | Carboplatin + PRO1184 PRO1184 Bevacizumab + PRO1184 Pembrolizumab + PRO1184 | Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (PRO1184-001) | Recruiting | USA | 1 |